PD-(L)1 inhibitor has been approved in the treatment of melanoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, renal cell cancer, and cervical cancer [118]. Here, CD274 is linked to renal cell adenocarcinoma.